| dc.contributor.author | Yilmaz, Mehmet Birhan | |
| dc.date.accessioned | 2019-07-27T12:10:23Z | |
| dc.date.accessioned | 2019-07-28T09:40:24Z | |
| dc.date.available | 2019-07-27T12:10:23Z | |
| dc.date.available | 2019-07-28T09:40:24Z | |
| dc.date.issued | 2017 | |
| dc.identifier.issn | 1016-5169 | |
| dc.identifier.uri | https://dx.doi.org/10.5543/tkda.2017.52358 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12418/6673 | |
| dc.description | WOS: 000418481800003 | en_US |
| dc.description | PubMed ID: 28947724 | en_US |
| dc.description.abstract | The GEMINI-ACS-1 trial has recently been published. It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes (ACS). The trial is important to set light to future of ACS management. | en_US |
| dc.language.iso | tur | en_US |
| dc.publisher | TURKISH SOC CARDIOLOGY | en_US |
| dc.relation.isversionof | 10.5543/tkda.2017.52358 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | After the GEMINI-ACS-1 trial | en_US |
| dc.type | article | en_US |
| dc.relation.journal | TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY | en_US |
| dc.contributor.department | [Yilmaz, Mehmet Birhan] Cumhuriyet Univ, Tip Fak, Kardiyol Anabilim Dali, TR-58140 Sivas, Turkey | en_US |
| dc.contributor.authorID | YILMAZ, MEHMET BIRHAN -- 0000-0002-8169-8628 | en_US |
| dc.identifier.volume | 45 | en_US |
| dc.identifier.endpage | 9 | en_US |
| dc.identifier.startpage | 8 | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
